Thus, by therapeutically increasing the expression of FKBP9 (downregulated in all three cancer nodules with respect to “Z”), the expressions of its synergistic partner genes would be pushed up, while the antagonistically expressed ones would be pushed down. The gene discussed is FKBP9; the disease is cancer.